Occult primary, version 3.2014.

Journal Article (Journal Article)

The NCCN Guidelines for Occult Primary tumors provide recommendations for the evaluation, workup, management, and follow-up of patients with occult primary tumors (cancers of unknown primary). These NCCN Guidelines Insights summarize major discussion points of the 2014 NCCN Occult Primary panel meeting. The panel discussed gene expression profiling (GEP) for the identification of the tissue of origin and concluded that, although GEP has a diagnostic benefit, a clinical benefit has not been demonstrated. The panel recommends against GEP as standard management, although 20% of the panel believes the diagnostic benefit of GEP warrants its routine use. In addition, the panel discussed testing for actionable mutations (eg, ALK) to help guide choice of therapy, but declined to add this recommendation.

Full Text

Duke Authors

Cited Authors

  • Ettinger, DS; Handorf, CR; Agulnik, M; Bowles, DW; Cates, JM; Cristea, M; Dotan, E; Eaton, KD; Fidias, PM; Gierada, D; Gilcrease, GW; Godby, K; Iyer, R; Lenzi, R; Phay, J; Rashid, A; Saltz, L; Schwab, RB; Shulman, LN; Smerage, JB; Stevenson, MM; Varadhachary, GR; Zager, JS; Zhen, WK; Bergman, MA; Freedman-Cass, DA; National Comprehensive Cancer Network,

Published Date

  • July 2014

Published In

Volume / Issue

  • 12 / 7

Start / End Page

  • 969 - 974

PubMed ID

  • 24994917

Pubmed Central ID

  • 24994917

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2014.0093

Language

  • eng

Conference Location

  • United States